drugset / Trial / NCT03411031
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Phase 2
Terminated
18 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance for each study arm.
Timeline
- Start
- 2018-10-04
- Primary completion
- 2021-02-18
- Completion
- 2021-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Elotuzumab | Monoclonal antibody | 20 mg/kg | Intravenous |
| Comparator | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Comparator | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Comparator | Dexamethasone | Small molecule | — | — |